Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 2
1998 1
1999 3
2000 3
2001 1
2002 5
2003 2
2004 5
2005 4
2006 3
2007 8
2008 5
2009 3
2010 3
2011 3
2012 4
2013 6
2014 5
2015 2
2016 13
2017 10
2018 7
2019 8
2020 5
2021 8
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17054107

118 results

Results by year

Filters applied: . Clear all
Page 1
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Bajetta E, et al. Cancer. 2006 Nov 15;107(10):2474-81. doi: 10.1002/cncr.22272. Cancer. 2006. PMID: 17054107 Free article. Clinical Trial.
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P. Pavel M, et al. Eur J Cancer. 2021 Nov;157:403-414. doi: 10.1016/j.ejca.2021.06.056. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597974 Free article. Clinical Trial.
The safety of lanreotide for neuroendocrine tumor.
Godara A, Siddiqui NS, Byrne MM, Saif MW. Godara A, et al. Expert Opin Drug Saf. 2019 Jan;18(1):1-10. doi: 10.1080/14740338.2019.1559294. Epub 2018 Dec 24. Expert Opin Drug Saf. 2019. PMID: 30582380 Review.
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Faiss S, et al. J Clin Oncol. 2003 Jul 15;21(14):2689-96. doi: 10.1200/JCO.2003.12.142. J Clin Oncol. 2003. PMID: 12860945 Clinical Trial.
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A, Maintz C, Müller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Rinke A, et al. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):500-509. doi: 10.1055/a-1342-2755. Epub 2021 Jul 22. Exp Clin Endocrinol Diabetes. 2021. PMID: 34293802 Free PMC article. Clinical Trial.
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Lepage C, et al. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11. Dig Liver Dis. 2017. PMID: 28292641 Clinical Trial.
118 results